<DOC>
	<DOCNO>NCT01447927</DOCNO>
	<brief_summary>This randomized phase II trial study well metformin hydrochloride work prevent esophageal cancer patient Barrett esophagus . Chemoprevention use certain drug keep cancer forming . The use metformin hydrochloride may keep esophageal cancer forming .</brief_summary>
	<brief_title>Metformin Hydrochloride Preventing Esophageal Cancer Patients With Barrett Esophagus</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare percent change mean pS6K1 immunostaining baseline mucosal Barrett esophagus ( BE ) biopsies among patient assign 2,000 mg metformin hydrochloride daily ( QD ) versus placebo determine Barrett mucosal biopsy sample obtain pre- post-intervention . SECONDARY OBJECTIVES : I . To evaluate adverse event associate two intervention arm . TERTIARY OBJECTIVES : I . To assess effect metformin hydrochloride 2,000 mg QD versus placebo change pS6K1 use traditional IHC category . II . To assess effect metformin hydrochloride 2,000 mg QD versus placebo absolute change pS6K1 . III . To assess change serum marker ( metformin hydrochloride , fast insulin , HOMA-IR , IGF-1 , IGF-2 , IGFBP-1 , IGFBP-3 , fast leptin , fast adiponectin ) determine serum sample obtain pre- post-intervention . IV . To assess change proliferation ( Ki-67 ) apoptosis ( cleaved caspase 3 ) determine Barrett mucosal biopsy sample obtain pre- post-intervention . V. To assess change molecular mediator insulin pathway ( p-IRS-1 , p-AKT^Serine 473 ) determine Barrett mucosal biopsy sample obtain pre- post-intervention . VI . To assess change relative activity AMPK ( phosphorylated AMPK/total AMPK ratio ) molecular mediator AMP kinase ( p-mTOR , pS6K1^Serine 235 ) determine Barrett mucosal biopsy sample obtain pre- post-intervention . VII . To assess change Programmed Cell Death 4 expression miR-21 determine Barrett mucosal biopsy sample pre- post-intervention . VIII . To establish biospecimen repository archive future correlative study . OUTLINE : This multicenter study . Patients stratify accord nonsteroidal anti-inflammatory drug use ( regular v regular ) , body mass index ( ≥ 30 kg/m² v &lt; 30 kg/m² ) , gender ( male v female ) , length Barrett ( 2.00 4.99 cm v ≥ 5.00 cm ) . Patients randomize 1 2 treatment arm . Arm I : Patients receive extended-release metformin hydrochloride orally ( PO ) daily ( QD ) week 1 , twice daily ( BID ) week 2-12 ( every morning [ QAM ] every evening [ QPM ] week 3 ) absence unacceptable toxicity disease progression . Arm II : Patients receive extended-release placebo PO QD week 1 BID week 2-12 ( QAM QPM week 3 ) absence unacceptable toxicity disease progression . Blood , tissue , mucosal tissue sample collect baseline completion study treatment pS6K1 analysis serum , mucosal , molecular marker study IHC , ELISA , western blotting , high-performance liquid chromatography ( HPLC ) method . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Histologically confirm diagnosis Barrett esophagus , dysplasia , indeterminate dysplasia , lowgrade dysplasia define presence specialize columnar epithelium histology &gt; = 2 cm involvement endoscopy Adequate Barrett mucosa , define &gt; = 1 4 research sample ( i.e. , &gt; = 25 % ) &gt; = 50 % intestinal metaplasia biopsy require satisfy endpoint study No history esophageal carcinoma cancer ( ) ( except nonmelanoma skin cancer ) No erosive esophagitis ulcerative esophagitis , unless treatment proton pump inhibitor ( PPI ) result heal erosion ulcer prior entry endoscopy No history highgrade dysplasia cancer ( confirm locally esophagogastroduodenoscopy [ EGD ] Pathology report ) No ulcer , plaque , nodule , stricture , luminal irregularity within Barrett segment , unless clinical biopsy produce evidence highgrade dysplasia cancer ECOG performance status = &lt; 1 Hemoglobin &gt; = 10 g/dL Leukocytes &gt; = 3,000/mL ( &gt; = 2,500/mL AfricanAmerican participant ) Absolute neutrophil count &gt; = 1,500/mL ( &gt; = 1,000/mL AfricanAmerican participant ) Platelets &gt; = 100,000/mL Total bilirubin = &lt; institutional upper limit normal ( ULN ) AST ( SGOT ) ALT ( SGPT ) = &lt; 1.5 time institutional ULN Creatinine = &lt; institutional ULN Willingness provide tissue sample research purpose No contraindication esophagogastroduodenoscopy ( EGD ) Willingness , men woman , use adequate contraception ( hormonal barrier method birth control ; surgical intervention ; abstinence ) prior study entry duration study participation A negative ( serum urine ) pregnancy test do = &lt; 7 day prior PreRegistration , woman childbearing potential No pregnant nursing woman No participant diabetes mellitus No history vitamin B12 deficiency megaloblastic anemia No history lactic acidosis No diseases associate weight loss : anorexia , bulimia , nausea No history allergic reaction attribute compound similar chemical biologic composition metformin No participant HIV , cirrhosis cause , NASH ( nonalcoholic steatohepatitis ) , hepatitis ( autoimmune infectious ) For participant diagnose hepatic impairment , consult protocol principal investigator ( PI ) No metabolic acidosis , acute chronic , include ketoacidosis No uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; include significant medical condition include renal failure , hepatic failure , sepsis , hypoxia No genetics disorder family history hereditary gastrointestinal polyp disorder ( e.g. , familial adenomatous polyposis [ FAP ] , hereditary nonpolyposis colorectal cancer [ HNPCC ] , PeutzJegher disease ) No chronic alcohol use history alcohol abuse ( define ingestion &gt; = 3 drink per day ) No kidney disease renal insufficiency ( define serum creatinine outside normal institutional limit ) Currently proton pump inhibitor ( PPI ) &gt; = 4 week ( PPI take least daily acceptable ) No medication ( ) weight loss ≤ 2 month prior PreRegistration No treatment medication may increase metformin hydrochloride level : cationic drug , e.g. , digoxin , amiloride , procainamide , ranitidine , trimethoprim , quinidine , quinine , vancomycin , triamterene , morphine No treatment oral hypoglycemic agent No participant use metformin , cimetidine ( Tagamet ) , furosemide ( Lasix ) , nifedipine ( Cardizem ) , drug contraindicate use metformin No receipt investigational agent = &lt; 3 month prior PreRegistration , except innocuous agent know interaction study agent ( e.g. , standard dose multivitamin topical agent limited skin condition ) , discretion Protocol Lead Investigator Participating Site No participant undergone ablation local therapy ( e.g. , percutaneous dilatational tracheostomy [ PDT ] , cryotherapy , radiofrequency , argon plasma coagulation [ APC ] , multipolar electrocoagulation [ MPEC ] ) Patients treat endoscopic mucosal resection [ EMR ] allow No participant anticipate elective surgery study period No participant plan undergo elective radiologic study involve intravascular administration iodinate contrast material</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>